PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms
Metrics: PDF 1294 views | HTML 1642 views | ?
Xiao-Lan Li1,2,*, Jianbiao Zhou1,*, Zit-Liang Chan1, Jing-Yuan Chooi1, Zhi-Rong Chen2, Wee-Joo Chng1,3,4
1Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, Singapore 117599, Republic of Singapore
2Department of Gastroenterology, Suzhou Municipal Hospital (Eastern), Suzhou City, Jiangsu Province, 215001, P.R. China
3Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Republic of Singapore
4Department of Hematology-Oncology, National University Hospital, Singapore 119228, Republic of Singapore
*These authors have contributed equally to this work
Wee-Joo Chng, e-mail: email@example.com
Zhi-Rong Chen, e-mail: firstname.lastname@example.org
Keywords: colorectal cancer (CRC), p53, tumor suppressor gene (TSG), PRIMA-1met, targeted therapy
Received: July 14, 2015 Accepted: September 17, 2015 Published: October 01, 2015
PRIMA-1met (APR-246) is a methylated derivative and structural analog of PRIMA-1 (p53 re-activation and induction of massive apoptosis). PRIMA-1met has been reported to restore both the wild type (wt) structure and function of mutant p53. Here, we show that PRIMA-1met is highly effective at limiting the growth of CRC cells regardless of p53 status. However, PRIMA-1met induces robust apoptosis only in CRC cells with mutant p53. Upregulation of Noxa, a proapoptotic molecule, is crucial for PRIMA-1met mediated activity. In human xenograft model of disease, PRIMA-1met effectively suppresses CRC tumor growth. Our results uncover distinct mechanisms of PRIMA-1met in CRC with different p53 status, thus providing a mechanistic rationale to evaluate the clinical efficacy of PRIMA-1met in CRC patients with different p53 status.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.